San Diego – December 2, 2014 – Cooley advised Ionis Pharmaceuticals, Inc. on its Rule 144A offering of $500 million aggregate principal amount of convertible senior notes due 2021. The initial purchasers have purchased $15 million aggregate principal amount of convertible notes.
Ionis is the leading company in antisense drug discovery and development; exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.
The Cooley team advising Ionis Pharmaceuticals was led by partners Charlie Kim, Gian-Michele a Marca and Sean Clayton, and included associates Jon Russo, Jason Savich, Phillip McGill and Adrienne Directo. Critical support was also provided by partner Natasha Leskovsek (health care and life sciences regulatory); and partners Susan Cooper Philpot and Mark Windfeld-Hansen (tax).
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has 800 lawyers across 11 offices in the United States and China.